Capecitabine but not 5-FU worsened hepatosplenomegaly and liver function when used with oxaliplatin and cetuximab as first-line treatment in K-ras wild-type metastatic colorectal cancer

Abstract

Theme: Building Bridges to Conquer CancerThis abstract will not be presented at the 2013 ASCO Annual Meeting but has been published in conjunction with the meeting - http://meetinglibrary.asco.org/content/113435-132BACKGROUND: MRC COIN study showed that OXA and CAP (CAPOX) have greater toxicities compared with OXA and 5-FU (FOLFOX) when cetuximab (C225) was added for mCRC. Meanwhile, OXA was associated with splenomegaly and hepatic sinusoidal injury. We investigated if CAPOX+C225 worsened hepatosplenomegaly and liver function compared with FOLFOX+C225 in K-rasWT mCRC. METHODS: 97 patients with K-ras WT mCRC received either FOLFOX or CAPOX ...link_to_OA_fulltex